ArticleProbiotics and antimicrobial proteins2025
Efficacy Evaluation of Selenium-enriched Akkermansia muciniphila in the Treatment of Colon Tumor Mice.
Article in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Regulation Progresses of Selenium Improving Intestinal and Extra-Intestinal Tissues Health Through Regulating Gut Microbiota.Biology · 2026Review
- Gut microbiota: a new perspective for bioavailability of selenium and human health.NPJ science of food · 2025Review
- The role and challenges of intratumoral microbiota in colorectal cancer immunotherapy.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Selenium (Se)-enriched probiotics possess a variety of beneficial properties and are widely used in specialty foods and biomedical applications. Akkermansia muciniphila (AM) is being considered a promising candidate for the "next generation probiotics (NGPs)," which play an essential role in the field of tumor therapy. However, there are no studies on the efficacy of Se-enriched A. muciniphila (Se-AM) in the field of tumor therapy. The present study utilized inorganic Se bio-enrichment for the preparation of Se-AM. To evaluate the killing effect of Se-AM on CT26 cells, the actual efficacy and safety of Se-AM were investigated in a mouse model of colon cancer. The results showed that the Se-AM-cell lysate was able to significantly kill CT26 cells, but this killing effect was progressively weakened with decreasing concentrations of Se-AM-cell lysate. The results of animal experiments showed that Se-AM was able to safely and effectively curb the disease course of mice with colon tumors, reduce the tumor volume, lower the levels of IL-1β and IL-6, and increase the levels of TNF-α in the colon of mice. Furthermore, treatment with Se-AM in mice led to a restoration of gut microbiota diversity, reaching levels similar to those observed in healthy controls. This restoration was accompanied by a significant enrichment of beneficial genera, such as Turicibacter, Butyricimonas, Prevotella, and Akkermansia. In summary, Se-AM prepared in this study was able to produce effective killing of CT26 cells directly and played a substantial therapeutic role in a mouse model of colon tumors constructed from CT26 cells. Se-AM had no adverse effect on the heart, liver, spleen, lungs, and kidney of mice and demonstrated a high level of safety. Meanwhile, Se-AM significantly raised the level of the Shannon index and the ratio of Firmicutes to Bacteroidetes of the gut microbiota in mice, indicating its ability to regulate the homeostasis of the microbiota. These results imply that Se-AM has great application value in the field of colon cancer treatment.
Indexed as
Identifiers
40011384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.